TThis is a MUST view for anybody that ever takes care of a hospitalized medically ill patient! with Alfonso Tafur MD MS MBA and Alex Spyropoulos youtu.be/pOcxVNc96GU?si…

🫀Every patient you help starts with the knowledge you carry. At VLN, we believe education saves lives—which is why our CME & CPE programs are designed to empower the clinicians at the heart of vascular care. Evidence-based. Created by experts who care deeply—just like you.

Good news once again Our manuscript on the association between hemoglobin values at baseline and clinical outcomes in patients with acute venous thromboembolism has been accepted for publication in Am J Hematol Congratulations, RIETE group!

Sobreviviste un coágulo? No estás solo. This #VTE support group is 4 U Queremos escucharte y acompañarte en este camino. Let’s build community, share stories, and take control. #BloodClotSurvivor Vasculearn Network #PacienteInformado #ThrombosisAwareness vln.thrombosis.org/c/patient-even…

Need to do better for #PE risk stratification, beyond reductionist models. In an European Society of Cardiology Journals #EHJ paper we show that a multimarker calculator🌡️outperforms the ESC model. Great work by David Jiménez 🇪🇸 manuel monreal et al #RIETE! Honored to be a part of it 👇: tinyurl.com/trpmzbrd

Good correlation between #DOAC anti-Xa assays: implications for future standardization doi.org/10.1016/j.rpth… Vasculearn Network Anticoagulation Forum The PERT Consortium® Thrombosis Canada CanVECTOR Network Thrombosis UK European Thrombosis & Haemostasis Alliance (ETHA) World Thrombosis Day C. Michael Gibson MD European Society of Cardiology Cardiology Today ISTH

We want to learn from you! How do you evaluate heavy menstrual bleeding in patients on anticoagulation. Take our survey: redcap.link/f8v5m0si CardioNerds ISTH ASH PERT Consortium World Thrombosis Day Shematologist, MD Professor Beverley Hunt OBE (also on BlueSky) Alisa Wolberg @fnainle

Find it here: pubmed.ncbi.nlm.nih.gov/40357649/

Find it here: pubmed.ncbi.nlm.nih.gov/40389232/

🇨🇦 Survey from Thrombosis Canada in @ThiemeMedical: > 50% of Canadians with cancer have little or no awareness of cancer-associated thrombosis (CAT) — a leading cause of death in cancer. 📊 Only 27% recalled education on CAT risks; most want more info! 👉 doi.org/10.1055/a-2635…

Why Cancer Patients Face Clot Risks (and How We Manage Them) youtu.be/PHL7GANsSNE?si… with Alfonso Tafur MD MS MBA and Grigoris Gerotziafas #CancerResearch #CancerTreatment

The impact of cancer site on outcomes in patients with acute VTE The #RIETEregistry experience

The risk of the composite of fatal PE or recurrent VTE within 90 days is much higher than major bleeding in lung, breast, hematologic or pancreatic cancers No major differences in GU or CI cancers Should all cancer patients with acute VTE receive the same treatment strategy?

📢Listen to the 🆕 "Clot, Clot" episode!🎙️ with Cassra N. Arbabi MD Donald Baril Efthymios “Makis” Avgerinos, MD, FACS, FEBVS a partnership🤝 between TH Thieme International and Vasculearn Network

Presented at #ESCCongress: In patients with provoked venous thromboembolism and ongoing risk factors, extended treatment with low-dose apixaban for 12 months resulted in a lower risk of recurrent VTE than placebo, with a low risk of major bleeding. Full HI-PRO trial results:

Absolutely incredible Gregory Piazza leading this NEJM Mass General Brigham Research #RCT!! 👏👏 nejm.org/doi/full/10.10… It's rare that a single institution RCT is powered for clinical outcomes. #thrombosis #VTE #Anticoagulation Honored to share 5 ys of this journey w you & team.

The VTE-PREDICT score to identify VTE patients at increased risk for bleeding or recurrence, externally validated using #RIETEregistry data Congrats, Tim and team!